Statins have been reported to protect against esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus (BE). However, there are few data from adequately powered cohort studies of subjects with BE. METHODS: We conducted a nested case-control study of a cohort of BE patients identified from national Veteran Affairs (VA) outpatient files, diagnosed with BE from 2004 through 2009. New cases of EAC recorded after BE diagnosis were identified during a follow-up period that ended in 2011 and verified using electronic medical records. We selected patients with BE without EAC (controls) using incidence density sampling; 3 controls were matched to each case based on birth year and date of BE diagnosis. Our analysis included only male patients with at least 1 VA visit per year of follow up. We identified prescriptions for statins and non-statin lipid lowering medications filled after BE diagnosis and up to 90 days before EAC diagnosis for cases and controls (during the corresponding time period); we examined the association between statin use and EAC in conditional logistic regression models. RESULTS: We compared 311 EAC cases to 856 controls. Cases were less likely to use any statins than controls (40.2% vs 54.0%; P < .01). Significantly lower proportions of cases used statins for 6-18 months (10.0% cases vs 17.1% controls) and >18 months (19.3% vs 24.0%, respectively; P < .01). Simvastatin was the most commonly prescribed statin (accounting for 86.9% of statin use); the defined daily dose of simvastatin was lower in cases than in controls (21-40 mg/day, 9.3% vs 14.5%, respectively; and >40 mg/day, 8.4% vs 12.6%, respectively; P < .01). In multivariate analysis, statin use was inversely associated with development of EAC (adjusted odds ratio [OR], 0.65; 95% confidence interval [CI], 0.47-0.91). This protective association was strongest for patients with advanced-stage EAC: in a stratified analysis, comparison of 189 cases with stage 0-1 EAC to 520 controls produced an adjusted OR of 0.85 (95% CI, 0.54-1.33). Among patients with late-stage EAC (stages 2-4, n ¼ 106) and 291 controls, the adjusted OR was 0.44 (95% CI, 0.25-0.79). We found no association between EAC and non-statin lipid-lowering medications. CONCLUSIONS: In a case-control study of US veterans, statin use among those with BE appeared to decrease the risk of EAC. This protective effect was strongest against advanced-stage EAC, and increased with statin dose.
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BACKGROUND & AIMS:
Statins have been reported to protect against esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus (BE). However, there are few data from adequately powered cohort studies of subjects with BE.
METHODS:
We conducted a nested case-control study of a cohort of BE patients identified from national Veteran Affairs (VA) outpatient files, diagnosed with BE from 2004 through 2009. New cases of EAC recorded after BE diagnosis were identified during a follow-up period that ended in 2011 and verified using electronic medical records. We selected patients with BE without EAC (controls) using incidence density sampling; 3 controls were matched to each case based on birth year and date of BE diagnosis. Our analysis included only male patients with at least 1 VA visit per year of follow up. We identified prescriptions for statins and non-statin lipid lowering medications filled after BE diagnosis and up to 90 days before EAC diagnosis for cases and controls (during the corresponding time period); we examined the association between statin use and EAC in conditional logistic regression models. RESULTS: We compared 311 EAC cases to 856 controls. Cases were less likely to use any statins than controls (40.2% vs 54.0%; P < .01). Significantly lower proportions of cases used statins for 6-18 months (10.0% cases vs 17.1% controls) and >18 months (19.3% vs 24.0%, respectively; P < .01). Simvastatin was the most commonly prescribed statin (accounting for 86.9% of statin use); the defined daily dose of simvastatin was lower in cases than in controls (21-40 mg/day, 9.3% vs 14.5%, respectively; and >40 mg/day, 8.4% vs 12.6%, respectively; P < .01). In multivariate analysis, statin use was inversely associated with development of EAC (adjusted odds ratio [OR] , 0.65; 95% confidence interval [CI] , 0.47-0.91). This protective association was strongest for patients with advanced-stage EAC: in a stratified analysis, comparison of 189 cases with stage 0-1 EAC to 520 controls produced an adjusted OR of 0.85 (95% CI, 0.54-1.33). Among patients with late-stage EAC (stages 2-4, n ¼ 106) and 291 controls, the adjusted OR was 0.44 (95% CI, 0.25-0.79). We found no association between EAC and non-statin lipid-lowering medications. CONCLUSIONS: In a case-control study of US veterans, statin use among those with BE appeared to decrease the risk of EAC. This protective effect was strongest against advanced-stage EAC, and increased with statin dose.
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T he incidence and mortality of esophageal adenocarcinoma (EAC) has been rising in the United States since the early 1970s. 1 The overall 5-year survival for patients with EAC in the United States is quite low at approximately 17%, ranging from 2.8% for those with advanced disease to 50% for localized disease. [1] [2] [3] For the purposes of EAC prevention, the known modifiable risk factors for EAC include gastroesophageal reflux disease (GERD), current smoking, a diet high in fats, and abdominal obesity. 2, 4 The high mortality rate and awareness of modifiable risk factors produces strong interest in chemoprevention, including proton pump inhibitors (PPI), aspirin, and nonsteroidal anti-inflammatory drugs (NSAID). [5] [6] [7] 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (ie, statins) are a class of medications that may also have a chemopreventive effect against the development of EAC in experimental studies using animal models. [8] [9] [10] However, the translational relevance of these findings to human populations is less clear. Additionally, unlike interventions that can be applied to the general population (eg, maintaining optimal body mass index or reducing dietary fat), EAC chemoprevention with statins needs to be studied in and applied to high-risk groups.
Two systematic reviews and meta-analyses of published literature have reported an inverse association between statin use and EAC risk in patients with BE (41-43% lower odds) in observational studies. 11, 12 However, the studies included in these reviews are quite limited, because most did not examine EAC among populations with Barrett's esophagus (BE), many did not distinguish between histologic subtypes of esophageal cancer or between high-grade dysplasia and EAC, and most studies did not account or adjust for important confounders. 11 Additionally, these meta-analyses did not find significant statin dose or duration relationships with EAC risk. 11, 12 BE is the only known precursor lesion for EAC 2 and is readily detectable on endoscopic examination; therefore, patients with BE represent the ideal group for EAC chemoprevention. Importantly, in these aforementioned reviews, there were only 4 studies that examined the effect of statins on EAC risk among patients with BE, and these studies arrived at conflicting findings. The first study was a nested case-control study in a BE cohort of United States veterans, which evaluated 116 esophageal cancer cases of unclear histology and 696 controls and found that statins were associated with a reduced cancer risk (adjusted incidence density ratio, 0.55; 95% CI, 0.36-0.86). 13 However, that study found strong inverse associations even with short periods of statin use, raising concerns of uncontrolled confounding. 13 The second was a Dutch multicenter cohort study of 570 BE patients, of whom only 38 patients developed high-grade dysplasia or EAC, which found that statin use was associated with a reduced risk of neoplastic progression in men older than 60 years (adjusted hazard ratio, 0.46; 95% CI, 0.1-0.99) with no duration-response relationship.
14 On the other hand, a cohort study of 344 BE patients, 33 of whom developed high-grade dysplasia or EAC, reported that statin use was not associated with the risk of neoplasia (unadjusted hazard ratio, 0.73; 95% confidence interval [CI], 0.30-1.78). 15 Furthermore, statin use was not associated with a reduced risk of EAC (hazard ratio, 0.68; 95% CI, 0.30-1.54) in the fourth cohort of 411 BE patients (45 developed EAC) from the Seattle Barrett's Esophagus Study. 16 The inconsistent findings are likely related to small numbers of EAC examined in each study, which limits the precision of risk estimates as well as the ability to adjust for multiple confounders. This was further compounded by likely misclassification of EAC cases as either high-grade dysplasia or squamous cell cancer. Therefore, the question of statins' protective effect on EAC remains unanswered.
To further examine the association between use of statins and the risk EAC in BE and address some limitations of prior studies, we have used national Veterans Affairs (VA) patient data in conjunction with VA administrative data to conduct a nested case-control study of validated EAC cases developed in a large cohort of BE patients.
Methods

Study Population and Design
This is a nested case-control study in a cohort of BE patients identified from the national Veterans Health Administration (VHA) Inpatient and Outpatient Medical SAS datasets. We identified patients with a first diagnosis of BE (BE International . 17 The date of BE diagnosis was defined as the date of the first ICD-9 code for BE. We excluded BE patients with conditions diagnosed within 5 years prior to and up to the BE index date that might have affected the likelihood of developing EAC or represented prevalent cases of EAC; these conditions included any diagnosis of gastroesophageal cancer, gastroesophageal resection, or bariatric surgery. Given that EAC is 3-4 times more common in men than in women 2 and that 98% of veteran patients with BE are men, 18 we included only male patients with VA pharmacy use within 1 year after BE diagnosis and with at least 1 VA visit during each year of follow-up. To maximize the catchment of EAC, we identified new cases of esophageal or gastric cancer by ICD-9 code occurring after BE diagnosis and follow-up through September 30, 2011. We subsequently reviewed the entire VA electronic medical records of all cases by manual chart review for evidence of EAC, to ascertain diagnosis dates from endoscopy and histology reports, and to verify that the date of EAC diagnosis followed BE diagnosis in all cases. For controls, we used incidence density sampling to select 3 BE patients without ICD-9 codes for esophageal or gastric cancer individually matched to each EAC case based on birth year (±1 year) and BE diagnosis date (±3 years).
Data Collection
We obtained pharmacy records from the pharmacy clinical national data extract of the VHA Decision Support System data. We also used the Compensation and Pension Records Interchange (CAPRI) and Veterans Health Information Systems and Technology Architecture (VISTA), a fully electronic health record database for all VHA users nationwide, to abstract clinical information not found in the administrative datasets.
We identified prescriptions for statins filled (ie, dispensed) after BE diagnosis and up to 90 days prior to EAC diagnosis for cases or corresponding date in matched BE controls. Statins included simvastatin (Zocor), lovastatin (Mevacor, Altoprev), atorvastatin (Lipitor), fluvastatin (Lescol), pravastatin (Pravachol), and rosuvastatin (Crestor). We also obtained filled prescription data for non-statin lipid-lowering medications to serve as an internal control exposure, including fibrates (fenofibrate, gemfibrozil), bile acid sequestrants (cholestyramine, colestipol, colesevelam), cholesterol absorption inhibitors (ezetimibe), and nicotinic acid (niacin). Start and stop dates, daily dose, number of days supply, and number of pills were collected for each filled prescription.
For each study subject, we calculated the total duration of filled prescriptions by adding the duration of individual statin prescriptions irrespective of gaps between prescriptions. We also calculated the cumulative dose of filled simvastatin prescriptions, which is the most commonly prescribed statin in VA, by adding the dose of individual prescriptions (dose multiplied by the quantity of pills), and the defined daily dose (DDD) by dividing the total cumulative dose by the total days supplied.
Other study variables included birth date, race (white, black, other), body mass index (BMI) at the time of BE diagnosis, smoking, alcohol use, Deyo comorbidity score, 19 diagnosis of gastroesophageal reflux disease (GERD) before BE diagnosis, and use of proton pump inhibitors (PPI), histamine-2 receptor antagonists (H2RA), aspirin, and non-steroidal antiinflammatory drugs (NSAID).
As a surrogate for healthy user bias, we examined the propensity of patients to receive an EGD between BE diagnosis date and EAC diagnosis date or corresponding date for matched controls.
Statistical Analysis
We calculated the proportions of cases and controls with filled prescriptions for any statin (as well as non-statin lipid lowering medications). We examined the total duration of filled prescription for any statin as a categorical variable (0-6 months, 6-18 months, and >18 months), the cumulative dose, as well as the DDD of simvastatin use in cases compared with controls.
We examined differences between EAC cases and BE controls with respect to age, race (white, black, other), BMI (<25, 25-30, >30), smoking, alcohol use, Deyo comorbidity score, mean number of EGDs between BE diagnosis and EAC diagnosis or corresponding date for controls, propensity score to receive an EGD, diagnosis of GERD before BE, and use of medications such as PPI, H2RA, aspirin, and NSAID.
We constructed conditional logistic regression models to calculate odds ratios (ORs) and 95% CI for the association between statins and the risk of EAC. In the multivariate analyses, we retained factors with P < .1 in univariate analysis and adjusted for age, BMI, smoking, PPI use, H2RA use, NSAID use, and number of EGDs after BE and prior to EAC diagnosis for cases or corresponding date for matched controls.
To examine the robustness of the analyses, we planned 2 sensitivity analyses. First, because receiving statin prescriptions can vary by age in a nonlinear fashion, we further adjusted for age by limiting the study population to patients 50 years of age. In the second analysis, we tested the EAC stage-specific statin associations by conducting the analysis stratified by early stage EAC (stages 0-1) and late stage EAC cases (stages 2-4) compared to their respective matched controls.
We conducted all analyses using SAS version 9.1 software (SAS Institute, Cary, North Carolina).
Results
In a cohort of 29,536 patients with BE, 760 had ICD-9 codes for esophageal or gastric cancer after their BE index date, of which 466 cases were verified to have EAC by chart review. Incidence density matching was possible for 378 EAC cases and 1012 BE controls. Subsequent restriction to only patients with at least one VA visit in each year of follow up further limited the final study population to 311 BE with EAC cases and 856 matched BE without EAC controls (Table 1 shows the study cohort). Cases were significantly more likely than controls to be overweight or obese (P ¼ .04), smokers (P ¼ .02), and receive an EGD between BE diagnosis and EAC diagnosis or corresponding date than controls (P < .01). Cases were less likely to use PPIs (P < .01), H2RAs (P ¼ .004), or NSAIDs (P ¼ .04) than controls. However, there was no significant difference in alcohol use, Deyo comorbidity score, propensity to receive an EGD, having a GERD diagnosis, or aspirin use between cases and controls. There were also no significant differences in mean age (64.7 vs 64.5) or race (89.1% white vs 85.7%).
Cases were less likely than controls to have dispensed prescriptions for any statin (40.2% vs 54.0%, respectively; P < .01) ( Table 2) ; this finding persisted in the sensitivity analysis, limited to cases and controls 50 years of age (40.7% vs 54.8%, respectively; P < .01). Significantly lower proportions of cases used statins for 6-18 months (10.0% vs 17.1%, respectively) and >18 months (19.3% vs 24.0%, respectively; P < .01. Simvastatin was the most commonly prescribed statin (86.9%), and similar to the overall finding, cases were less likely to use simvastatin compared to controls (34.7% vs 47.0%, respectively; P < .01). A dose effect was seen, as cases had dispensed prescriptions with significantly lower cumulative simvastatin dose than cases (<15 g, 17.4% cases vs 25.9% controls; 15-30g, 10.0% vs 9.8%; 30-60g, 4.2% vs 6.3%; >60g, 3.2% vs 4.9%; P < .01). Furthermore, the DDD of simvastatin was lower in cases than controls (21-40 mg/day, 9.3% vs 14.5%; >40mg/day, 8.4% vs 12.6%; P < .01). We found a significant interaction between statin and PPI use, where the decreased risk of EAC was more pronounced among those with concomitant PPI use (P ¼ .065) with an adjusted OR of 0.59 (data not shown). We found no significant interaction between statin use and NSAID use (P > .1).
In the multivariate conditional regression model evaluating statin duration in EAC cases versus BE controls, no association was seen with statin use <6 months compared to no use (adjusted OR, 0.82; 95% CI, 0.52-1.31); however, a protective, inverse association was seen in EAC cases with statin use of 6-18 months (adjusted OR, 0.52; 95% CI, 0.32-0.85) compared to no use. A protective association was also found in EAC cases with statin use >18 months, although this did not reach statistical significance after adjusting for age at BE diagnosis, smoking, BMI, PPI use, H2RA use, NSAID use, and number of EGDs between BE diagnosis and EAC diagnosis date or corresponding date in controls (adjusted OR, 0.64; 95% CI, 0.40-1.01).
In stage-specific stratified analyses, the inverse association between filled statin prescriptions and EAC was observed only for late stage cases. Comparing 106 late stage EAC cases (stages 2-4) to 291 matched controls, the adjusted OR was 0.44 (95% CI, 0.25-0.79). In comparison, in 189 cases with early stage EAC (stages 0-1) and 520 matched controls without EAC, the adjusted OR for any statin use was 0.85 (95% CI, 0.54-1.33).
We found no significant associations between EAC risk and filled prescriptions for non-statin lipid-lowering medications (bile acid sequestrants, P ¼ 0.95; fibrates, P ¼ .62; niacin, P ¼ .72; cholesterol absorption inhibitors, P ¼ .54; Table 4 ).
Discussion
Our study shows that statins may have a chemopreventive effect against the development of EAC in patients with BE. Subjects with BE who had dispensed prescriptions of statin had an approximately 35% lower odds of developing EAC than those who had no statin prescriptions after multiple adjustments for possible confounders. Most of the risk reduction was evident in patients with late stage EAC. Additionally, we observed duration-relationship, as longer duration of statin use (> 6 months) was protective against EAC development (36-48% odds reduction compared with no use) but this effect attenuated with statin durations > 18 months. The effect on EAC reduction was specific to statins and was not seen for the other non-statin lipid lowering medications.
Previous small observational studies have examined the use of statins and the development of EAC in patients with BE and arrived at conflicting results. Nguyen et al 15 examined 344 BE controls and 33 patients with BE who developed high-grade dysplasia or EAC and found that statin use was not significantly associated with the risk of EAC in BE patients (unadjusted HR, 0.73; 95% CI, 0.30-1.78). 15 A prospective, multicenter study conducted at Dutch hospitals followed 570 BE patients for more than 3.5 years with 38 incident cases of high-grade dysplasia or EAC and found that statin use protected against EAC development only in men over 60 years of age (adjusted HR, 0.46; 95% CI, 0.21-0.99), however no duration effect was observed.
14 A cohort study from the Seattle Barrett's Esophagus Study of 411 controls and 56 EAC cases limited the analyses to only those with high-grade dysplasia at baseline and found that statin use reduced the risk of EAC after adjusting for age, sex, and smoking (HR, 0.31; 95% CI, 0.11-0.86); however, when NSAID use was added to the model, the findings were no longer significant (HR, 0.41; 95% CI, 0.13-1.26). 15 These studies were likely inadequately powered (number of EAC cases in BE ranged from 33 to 116) to allow to detect small effects or to adjust for multiple important confounders.
Of the 4 previous studies that examined statin effect on EAC risk in patients with BE, 2 reported no significant associations. 15, 16 The magnitude of risk reduction observed in our study was generally similar to that observed in the 2 studies that showed a possible benefit of statins (45% and 54%, respectively). 13, 14 However, our study examined a much larger number of EAC cases, had minimal potential for case/control misclassification, and accounted for several important potential confounders, including PPI and NSAID use. Further, the current study suggests a dose-and duration-relationship among EAC cases and BE controls in the United States, especially for those with statin prescriptions >6 months (36-48% reduction in EAC risk compared to those with no statin prescriptions). One previous study found a duration-response relationship between statin use and EAC development (P ¼ .02 for trend test); however, most of the risk reduction was observed between no use and 1 to 12 months of statin use, raising concerns of uncontrolled confounding. 13 Experimental studies have suggested several mechanisms for the association between statin use and the reduced odds of developing EAC. [8] [9] [10] Simvastatin was shown to attenuate cell surface ICAM-1 expression as well as nuclear factor-kappa beta activation in human EAC cells, thereby attenuating growth by decreasing cell viability and attenuating metastatic potential by decreasing expression of key metastatic markers. 10 Additionally, simvastatin has been shown to cause a significant reduction in Bcl-2 expression (an antiapoptotic protein) and an increase in Bax expression (a proapoptotic protein). 8 EAC chemoprevention with statin has equivocal effectiveness among the broader population of patients with any risk for EAC, but has clearer evidence of benefit among highrisk groups. Our study demonstrates that patients with BE have an approximate 39% reduction in EAC risk with statin use. An even higher risk reduction was found when analysis was limited to only those with late stage EAC. It is unclear whether biological or health service use factors account for this finding; however, it may suggest that at-risk patients taking statins are more likely to present at an earlier and more treatable cancer stage.
Our study incidence density sampling is the method of choice for obtaining unbiased results in pharmacoepidemiological studies. 20 Cohort studies frequently yield a small number of detected cases (as seen in the studies previously mentioned) but a very large number of control subjects who are not likely to ever develop disease. This leads to 2 very different comparison groups and, thus, uncontrolled confounding. A major strength of this study is the utilization of incidence density sampling, which allows for the selection of an unbiased referent group by including BE controls that may later become EAC cases, thus minimizing confounding of the results.
Statins could be a cost-effective chemoprevention option among patients with BE. A cost-effectiveness analysis by Choi et al 21 constructed a decision analytic Markov model and compared 4 strategies of BE management, endoscopic surveillance alone, aspirin therapy, statin therapy, and aspirin plus statin therapy. Patients taking aspirin daily were projected to have a 53% reduction in EAC incidence (our study showed 56% risk reduction with statin use among those with late stage EAC), while those who took a daily statin were modeled to have a 54% reduction, and patients who took both aspirin and statin had a 78% reduction. Choi et al 21 found that comparing statin therapy with aspirin therapy, the incremental cost-effectiveness ratio was $863,200 per quality-adjusted life years, which exceeded the study's willingness to pay. However, when statin therapy was compared with endoscopic surveillance alone, the incremental cost-effectiveness ratio was $37,640 per quality-adjusted life years, signifying that statin therapy may be cost-effective in patients who are unable to tolerate aspirin therapy. 21 The study included only male veterans, which, although similar to a substantial proportion of the BE population, may not be representative of the general population. Additionally, medication usage may not have been completely captured if participants received medications outside the VA pharmacies; however, limiting our study population to only those with a VA visit during each year of follow-up reduces the likelihood of this occurrence. 22 Last, despite use of incidence density and multiple adjustments, residual confounding may still be present.
Our study has multiple strengths. We identified all possible EAC cases from a cohort of BE patients using an expanded search strategy of automated data, and further verified cases through manual chart review of EAC and BE diagnoses. Additionally, we ensured that we had valid pharmacy records for subjects by including only those with VA visits per year of follow-up. We also adjusted for several important confounders, including PPI use, and healthy behavior surrogates, such as the propensity to receive an EGD.
In summary, we found a significant association between statin use among patients with BE and a decreased risk of subsequent development of EAC, especially with higher doses and longer duration of use. The findings of the current study suggest that a randomized clinical trial of chemoprevention including statins, ASA, and NSAIDs with and without BE surveillance and including intermediate biomarkers would fill an important scientific gap in the prevention of EAC. 23 
